Great Lakes Retirement Inc. Acquires Shares of 4,014 United Therapeutics Co. (NASDAQ:UTHR)

Great Lakes Retirement Inc. bought a new position in United Therapeutics Co. (NASDAQ:UTHR - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 4,014 shares of the biotechnology company's stock, valued at approximately $1,237,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Dunhill Financial LLC raised its stake in shares of United Therapeutics by 100.0% during the 4th quarter. Dunhill Financial LLC now owns 100 shares of the biotechnology company's stock worth $35,000 after buying an additional 50 shares in the last quarter. Sound Income Strategies LLC purchased a new position in United Therapeutics in the first quarter worth $49,000. State of Wyoming purchased a new position in United Therapeutics in the fourth quarter worth $62,000. Curat Global LLC acquired a new stake in United Therapeutics in the first quarter valued at $63,000. Finally, Millstone Evans Group LLC purchased a new stake in shares of United Therapeutics during the 4th quarter worth $67,000. Hedge funds and other institutional investors own 94.08% of the company's stock.

Insider Buying and Selling

In other news, Director Tommy G. Thompson sold 2,500 shares of the business's stock in a transaction on Monday, March 24th. The shares were sold at an average price of $318.80, for a total transaction of $797,000.00. Following the completion of the sale, the director now directly owns 8,480 shares of the company's stock, valued at $2,703,424. The trade was a 22.77% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Paul A. Mahon sold 11,000 shares of the stock in a transaction on Thursday, June 12th. The stock was sold at an average price of $279.96, for a total value of $3,079,560.00. Following the completion of the transaction, the executive vice president now directly owns 36,781 shares in the company, valued at $10,297,208.76. This trade represents a 23.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 79,500 shares of company stock valued at $23,907,950. Insiders own 10.30% of the company's stock.

Analysts Set New Price Targets

Several brokerages recently commented on UTHR. Wall Street Zen cut shares of United Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Friday, May 2nd. Bank of America decreased their price target on United Therapeutics from $321.00 to $315.00 and set a "neutral" rating on the stock in a research note on Wednesday, June 11th. HC Wainwright reissued a "buy" rating and issued a $425.00 target price on shares of United Therapeutics in a report on Monday, May 5th. Cantor Fitzgerald started coverage on United Therapeutics in a research note on Monday, June 2nd. They set an "overweight" rating and a $405.00 price target for the company. Finally, JPMorgan Chase & Co. decreased their price objective on shares of United Therapeutics from $355.00 to $350.00 and set an "overweight" rating on the stock in a research report on Thursday, May 1st. Four investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $393.08.

United Therapeutics Trading Up 1.8%

United Therapeutics stock opened at $288.56 on Tuesday. The stock has a fifty day moving average price of $300.68 and a 200 day moving average price of $329.63. United Therapeutics Co. has a 52 week low of $266.98 and a 52 week high of $417.82. The firm has a market capitalization of $13.02 billion, a P/E ratio of 12.67, a PEG ratio of 0.97 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its quarterly earnings data on Wednesday, April 30th. The biotechnology company reported $6.63 EPS for the quarter, beating analysts' consensus estimates of $6.29 by $0.34. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The company had revenue of $794.40 million during the quarter, compared to the consensus estimate of $726.82 million. During the same quarter in the prior year, the company posted $6.17 EPS. The company's quarterly revenue was up 17.2% compared to the same quarter last year. As a group, equities analysts predict that United Therapeutics Co. will post 24.48 EPS for the current year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Co. (NASDAQ:UTHR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.